The Fat-Cure Hype Faces COLLAPSE. Tesamorelin Peptide Has a Cancer Warning.
Published Nov 12, 2026 · 16:23
Likes: 1KAvg views/h: 3K
Its recent uploads
#12 of its last 20 · its usual 673K
Its uploads we’ve seen, oldest left, by views (log scale). Dashed: its usual.
Performance in numbers
Figures as of Nov 15, 2026, 2:15 AM UTC.
The Fat-Cure Hype Faces COLLAPSE. Tesamorelin Peptide Has a Cancer Warning. by The Infographics Show has 232K views, 5 days after it was published on November 12, 2026.
It is getting 529 views an hour now, 0.4× what The Infographics Show’s uploads usually get (673K).
Its best day so far was Nov 12, with 174K views, and it is watched most around 10 AM UTC.
| Views | 232K | 232,076 |
|---|---|---|
| Views per hour now | 529 | |
| Times its channel’s usual | 0.4× | |
| Its channel’s usual per upload | 673K | 673,111 |
| Best day | Nov 12 · 174K | 174,402 |
| Busiest hour | 10 AM UTC | |
| Likes | 1K | 1,363 |
| Published | November 12, 2026 | |
| Length | 16:23 | |
| Category | Education | |
| Channel | The Infographics Show | |
| Channel subscribers | 16M |
Views
232K
Views/h now
529
▼ 64%
× usual
0.4×
its usual 673K
Views per day
174K
best day, Nov 12
When it’s watched
10 AM
its busiest hour, your time
Where it charts
Not on any chart we track right now.
From the YouTube record
Fields of the video as the YouTube API returns them.
- Published
- Nov 12, 2026, 2:11 AM
- Duration
- 16:23
- Category
- Education
- Audio language
- English (en)
- Title language
- English (en)
- Captions
- Yes
- Definition
- HD
- Format
- 2D
- License
- Standard YouTube
- Licensed content
- Yes
- Embeddable
- Yes
- Made for kids
- No
- Age-restricted
- No
- Paid promotion
- No
- Public stats
- Yes
Topics
- Health
- Knowledge
Title and description in 21 languages
- Arabic
- Bangla
- English
- Hindi
- Indonesian
- Italian
- Hebrew
- Japanese
- Korean
- Malayalam
- Punjabi
- Polish
- Russian
- Tamil
- Telugu
- Ukrainian
- German
- Spanish
- French
- Dutch
- Portuguese
Description
Tesamorelin is being promoted as a peptide that can target the dangerous visceral fat surrounding your organs, but how does it actually work? Unlike traditional weight-loss drugs, Tesamorelin doesn’t directly suppress appetite or simply burn calories. It mimics Growth Hormone-Releasing Hormone, or GHRH, signaling the pituitary gland to increase the body’s own natural pulses of growth hormone. That matters because visceral fat appears particularly sensitive to growth hormone signaling. Tesamorelin was originally developed to treat HIV-associated lipodystrophy, a condition that can cause dangerous abdominal fat accumulation in people receiving antiretroviral therapy. In 2010, the FDA approved it under the brand name Egrifta. Clinical trials found that Tesamorelin reduced visceral abdominal fat by roughly 15–20% without necessarily producing dramatic changes on the scale. Research has also explored potential effects on liver fat, metabolic health, inflammation, and even cognitive function. But manipulating the growth hormone axis comes with real trade-offs. Side effects can include injection-site reactions, joint pain, fluid retention, numbness, changes in glucose tolerance, and increased IGF-1 levels that require monitoring. Brand-name treatment can also cost thousands of dollars per month. And once treatment stops, much of the visceral fat can return. Tesamorelin may be one of the most clinically validated peptides available, but a smaller waistline can come with a much bigger commitment. 00:25 - How Tesamorelin Targets Visceral Fat 01:33 - The HIV Crisis That Led to Tesamorelin 02:36 - How Tesamorelin Activates Growth Hormone 05:02 - FDA Approval and the Rise of Egrifta 06:12 - What Clinical Trials Show About Visceral Fat Loss 08:59 - The Unexpected Effects on the Brain and Metabolism 11:50 - Side Effects, Glucose Risk and Cancer Concerns 14:14 - The High Cost, Gray Market and Rebound Problem Narrated by: Josh Risser 🔔 Don't forget to SUBSCRIBE! 🔔 SUGGEST A TOPIC: https://bit.ly/suggest-an-infographics-video 💬 Come chat with me: https://discord.gg/theinfoshow 🔖 MY SOCIAL PAGES TikTok ► https://www.tiktok.com/@theinfographicsshow Facebook ► https://www.facebook.com/TheInfographicsShow 📝 SOURCES: https://pastebin.com/jFxesu5h All videos are based on publicly available information unless otherwise noted.Show all
Tesamorelin is being promoted as a peptide that can target the dangerous visceral fat surrounding your organs, but how does it actually work? Unlike traditional weight-loss drugs, Tesamorelin doesn’t directly suppress appetite or simply burn calories. It mimics Growth Hormone-Releasing Hormone, or GHRH, signaling the pituitary gland to increase the body’s own natural pulses of growth hormone. That matters because visceral fat appears particularly sensitive to growth hormone signaling. Tesamorelin was originally developed to treat HIV-associated lipodystrophy, a condition that can cause dangerous abdominal fat accumulation in people receiving antiretroviral therapy. In 2010, the FDA approved it under the brand name Egrifta. Clinical trials found that Tesamorelin reduced visceral abdominal fat by roughly 15–20% without necessarily producing dramatic changes on the scale. Research has also explored potential effects on liver fat, metabolic health, inflammation, and even cognitive function. But manipulating the growth hormone axis comes with real trade-offs. Side effects can include injection-site reactions, joint pain, fluid retention, numbness, changes in glucose tolerance, and increased IGF-1 levels that require monitoring. Brand-name treatment can also cost thousands of dollars per month. And once treatment stops, much of the visceral fat can return. Tesamorelin may be one of the most clinically validated peptides available, but a smaller waistline can come with a much bigger commitment. 00:25 - How Tesamorelin Targets Visceral Fat 01:33 - The HIV Crisis That Led to Tesamorelin 02:36 - How Tesamorelin Activates Growth Hormone 05:02 - FDA Approval and the Rise of Egrifta 06:12 - What Clinical Trials Show About Visceral Fat Loss 08:59 - The Unexpected Effects on the Brain and Metabolism 11:50 - Side Effects, Glucose Risk and Cancer Concerns 14:14 - The High Cost, Gray Market and Rebound Problem Narrated by: Josh Risser 🔔 Don't forget to SUBSCRIBE! 🔔 SUGGEST A TOPIC: https://bit.ly/suggest-an-infographics-video 💬 Come chat with me: https://discord.gg/theinfoshow 🔖 MY SOCIAL PAGES TikTok ► https://www.tiktok.com/@theinfographicsshow Facebook ► https://www.facebook.com/TheInfographicsShow 📝 SOURCES: https://pastebin.com/jFxesu5h All videos are based on publicly available information unless otherwise noted.
◆ Calculated by viralshooter · all other figures from the YouTube API